The treatment was part of the company's clinical trial.
Medigus Ltd. (TASE:MDGS) today announced that three more procedures were successfully carried out in May with the company's SRS endoscope for the treatment of gastroesophageal reflux disease (GERD) in India. The procedures were part of the clinical trial required by the US Food and Drug Administration (FDA) for marketing approval of the endoscope.
The procedures were carried out at the Deenanath Mangeshkar Hospital in Pune. No serious adverse events were reported. Medigus is continuing with the multi-center trial.
Medigus' share price rose 3.3% in morning trading to NIS 1.60, giving a market cap of NIS 117 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 8, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010